Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or overweight.
At 36 weeks, 27.1% of patients receiving both drugs achieved complete skin clearance and at least 10% weight loss, compared to 5.8% of patients receiving Taltz alone, meeting the study’s primary endpoint, according to a Feb. 18 news release. In a key secondary measure, 40.6% of patients in the combination group reached complete skin clearance, compared to 29.0% in the monotherapy group.
The 274-participant study enrolled a population with an average BMI of more than 39 kilograms per square meter — the highest of any phase 3 psoriasis biologic trial to date. Nearly all patients had psoriasis affecting high-impact areas and most had approximately 25% body surface area involvement.
The study marks Taltz as the first biologic with data from two trials supporting use alongside an incretin therapy. Zepbound is the only FDA-approved dual GIP and GLP-1 receptor agonist for obesity management.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
